Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Completed No phase listed Observational Accepts healthy volunteers

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye

NCT04493658
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions
Questionnaires, Tear fluid sampling, Impression Cytology
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases, Keratoconjunctivitis, Eye Diseases, Keratitis, Corneal Disease, Ophthalmic Solution
Interventions
Systane Complete, Systane Ultra
Other
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Keratoconjunctivitis Sicca
Interventions
Rebamipide 1%, Rebamipide 2%, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 55 more
Conditions
Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Murrieta, California + 25 more
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal, Sham, Oculeve Extranasal
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Waterbury, Connecticut • Norfolk, Virginia
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Intranasal Lacrimal Neurostimulator (Oculeve)
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121, Placebo
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Conditions
Keratoconjunctivitis Sicca
Interventions
Rebamipide 1%, Rebamipide 2%, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Little Rock, Arkansas + 47 more
Conditions
Keratoconjunctivitis Sicca
Interventions
Pimecrolimus, Vehicle
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Lewiston, Maine + 2 more
Conditions
Dry Eye
Interventions
Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With DED

NCT03616899
Conditions
Kerato Conjunctivitis Sicca
Interventions
KPI-121 Ophthalmic Suspension, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

NCT00411827
Conditions
Keratoconjunctivitis Sicca
Interventions
PRK with conjunctival impression cytology before and after surgery, LASIK with conjunctival impression cytology before and after surgery
Procedure
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
21 Years to 40 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Dry Eye Syndrome
Interventions
TheraTears lubricating drops
Other
Lead sponsor
Jenkins Eye Care
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Keratoconjunctivitis Sicca
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Dry Eye
Interventions
Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Conditions
Dry Eye, Dry Eye, Evaporative, Dry Eye Disease, Evaporative Dry Eye, Evaporative Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Miebo
Drug
Lead sponsor
Gordon Schanzlin New Vision
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rush, New York
Conditions
Keratoconjunctivitis Sicca
Interventions
Systane Ocular Drops (OTC), Placebo - Saline Drops
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina